肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2013年
6期
447-450
,共4页
贾友超%魏亚宁%申红强%田彦敏%臧爱民
賈友超%魏亞寧%申紅彊%田彥敏%臧愛民
가우초%위아저%신홍강%전언민%장애민
回生口服液%IL-6%IL-18%非小细胞肺癌
迴生口服液%IL-6%IL-18%非小細胞肺癌
회생구복액%IL-6%IL-18%비소세포폐암
Hui-sheng oral liquid%IL-6%IL-18%Non-small-cell lung cancer
目的：检测回生口服液对晚期非小细胞肺癌患者血清IL-6和IL-18水平的影响，探讨其抗肿瘤的可能机制。方法将82例晚期非小细胞肺癌患者随机分为联合化疗组（NP方案化疗+回生口服液，42例）和单纯化疗组（NP方案，40例），化疗2个周期后评价其临床疗效，并用酶联免疫法（ELISA）检测各组治疗前后血清IL-6和IL-18的水平。结果联合化疗组总有效率为38.1％（16/42），单纯化疗组总有效率35.0％（14/40），差异无统计学意义（P=0.697）。单纯化疗组治疗前后血清IL-6和IL-18水平无显著性变化(P=0.623)。与治疗前比较，联合化疗组治疗后血清IL-6和IL-18水平明显升高（P=0.005）。结论回生口服液辅助治疗可提高晚期非小细胞肺癌患者的血清IL-6和IL-18水平，增强其免疫力。
目的：檢測迴生口服液對晚期非小細胞肺癌患者血清IL-6和IL-18水平的影響，探討其抗腫瘤的可能機製。方法將82例晚期非小細胞肺癌患者隨機分為聯閤化療組（NP方案化療+迴生口服液，42例）和單純化療組（NP方案，40例），化療2箇週期後評價其臨床療效，併用酶聯免疫法（ELISA）檢測各組治療前後血清IL-6和IL-18的水平。結果聯閤化療組總有效率為38.1％（16/42），單純化療組總有效率35.0％（14/40），差異無統計學意義（P=0.697）。單純化療組治療前後血清IL-6和IL-18水平無顯著性變化(P=0.623)。與治療前比較，聯閤化療組治療後血清IL-6和IL-18水平明顯升高（P=0.005）。結論迴生口服液輔助治療可提高晚期非小細胞肺癌患者的血清IL-6和IL-18水平，增彊其免疫力。
목적：검측회생구복액대만기비소세포폐암환자혈청IL-6화IL-18수평적영향，탐토기항종류적가능궤제。방법장82례만기비소세포폐암환자수궤분위연합화료조（NP방안화료+회생구복액，42례）화단순화료조（NP방안，40례），화료2개주기후평개기림상료효，병용매련면역법（ELISA）검측각조치료전후혈청IL-6화IL-18적수평。결과연합화료조총유효솔위38.1％（16/42），단순화료조총유효솔35.0％（14/40），차이무통계학의의（P=0.697）。단순화료조치료전후혈청IL-6화IL-18수평무현저성변화(P=0.623)。여치료전비교，연합화료조치료후혈청IL-6화IL-18수평명현승고（P=0.005）。결론회생구복액보조치료가제고만기비소세포폐암환자적혈청IL-6화IL-18수평，증강기면역력。
Objective To detect the effects of Hui-sheng oral liquid on the expression of Interleukin-6 and Interleukin-18 of patients with advanced non-small-cell lung cancer (NSCLC) and to investigate its possible anti-tumor mechanism. Methods Eighty-two patients with advanced NSCLC were recruited and randomly divided into two groups:the combined chemotherapy group (NP chemotherapy and hui-sheng oral liquid, n=42) and the single chemotherapy (only NP chemotherapy, n=40). The ef-fective rates were evaluated after two cycles’treatment. The expression of serum IL-6 and IL-18 were detected by the enzyme linked immunoassay (ELISA) before and after two cycles’treatment. Results The total effective rate was 38.1%(16/42) for the combined chemotherapy group, and 35.0%(14/40) for the single chemotherapy group;there was no significant difference (P=0.697) between the two groups. No difference was found in the expression of IL-6 and IL-18 before and after treatment in the single chemotherapy group (P=0.623). While compared with before treatment, the expression of both IL-6 and IL-18 were significantly up-regulated after treatment in combined chemotherapy group (P=0.005). Conclusion The adjuvant treatment with Hui-sheng oral liquid could increase the expression of IL-6 and IL-18 of patients with NSCLC and enhance their immunizing power.
